GERN GERON CORP

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Biopharmaceutical company focused on cancer therapeutics development
• • No new products, services, or segments introduced or emphasized in this filing year
• • Continued emphasis on corporate governance with established Code of Conduct and Insider Trading Policy
• • No quantitative metrics disclosed in Business section; governance details referenced extensively to Proxy Statement
• • Unusual fact: Entire Business section replaced by governance, ethics, and reference to Proxy Statement, lacking typical operational details

Risk Factors

• • Regulatory risk: Uncertainty in RYTELO approval beyond U.S. FDA and EU marketing authorization, affecting future launch timing and revenue generation
• • Macroeconomic risk: Exposure to inflation, trade tensions, interest rate fluctuations, and global crises impacting financing and operations
• • Supply chain risk: $60 million in manufacturing commitments for RYTELO requiring long lead-times and incurring cancellation penalties
• • Competitive risk: Potential market disruption if RYTELO commercialization fails or competitors advance alternative myelodysplastic syndrome treatments
• • Financial risk: $119.5 million long-term debt principal with covenants and maturity in 2029, plus $141 million net proceeds dilution risk from equity offerings

Management Discussion & Analysis

• • No revenue or profitability figures disclosed in MD&A section
• • No segment performance or dollar amounts provided
• • No cash flow, buybacks, dividends, or capital expenditure details reported
• • Risks focus on commercialization, regulatory approvals, clinical trial outcomes, manufacturing, and market acceptance of RYTELO (imetelstat)
• • Forward-looking risks include FDA/EC approval timelines, clinical trial delays, competitive pressures, and macroeconomic impacts on operations

What are the latest GERN SEC filings in 2026?

GERON CORP (GERN) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on May 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did GERN file its most recent 10-K annual report?

GERON CORP (GERN) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view GERN 10-Q quarterly reports?

GERON CORP (GERN)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every GERN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has GERN filed recently?

GERON CORP (GERN)'s most recent 8-K was filed on May 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find GERN insider trading activity (Form 4)?

SignalX aggregates every GERN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does GERN file with the SEC?

GERON CORP (GERN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new GERN filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for GERON CORP (GERN).

What is GERN's SEC CIK number?

GERON CORP (GERN)'s SEC CIK (Central Index Key) number is 886744. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 886744 to look up all GERN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find GERN return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from GERON CORP (GERN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.